Lung Cancer

This study found a substantial difference in the number of agents available for use in the metastatic and adjuvant settings for non-small cell lung cancer, breast cancer, and colon cancer.

Researchers found that using prophylactic cranial irradiation after thoracic radiation in patients with limited-stage small cell lung cancer undergoing contemporary head imaging is not associated with a decrease in risk of developing new brain metastasis.

Identifying early predictors of poor quality of life could allow for the identification of patients who may benefit from early referral to palliative and supportive care according to the researchers.

A prognostic survival model, titled PROVIEW, was able to accurately predict changing cancer survival risk over time and may have the potential to be a useful prognostic tool that can be completed by patients.

Researchers outlined recommendations for testing patients with lung cancer for COVID-19, given their specific cumulative risk factors for COVID-19 complications.

Researchers detailed the challenges presented for lung cancer therapy during the COVID-19 pandemic and how to potentially mitigate them.

Researchers examined the pathology of early-phase COVID-19 pneumonia in two older patients who were admitted to the hospital for adenocarcinoma procedures, but did not exhibit COVID-19 symptoms at the time of these procedures.

Experts present a case of recurrent small cell lung cancer presenting with a cutaneous metastatic nodule in the right breast.

Bristol Myers Squibb recently announced that the FDA granted priority review to nivolumab plus ipilimumab in combination with chemotherapy as a first-line treatment for metastatic NSCLC.

The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.

Researchers determined that artificial intelligence could help predict responses to systemic therapies for patients with non-small cell lung cancer by utilizing CT scans.

The FDA approved durvalumab (Imfinzi) as a first-line treatment for adult patients with extensive-stage small cell lung cancer in combination with standard-of-care chemotherapies, etoposide plus either carboplatin or cisplatin.

Researchers reported on the incidence and outcomes of the SARS-CoV-2 infection, which has been linked to COVID-19, in patients with cancer who were treated at a tertiary cancer institution in Wuhan, China.

In this study, polypharmacy during the 6-month time period pre-IV chemotherapy was highly predictive of post-chemotherapy inpatient hospitalization.

This study examined the acquired resistance found from treatment with third-generation EGFR TKIs to see if it was associated with diverse pathways, with an eye for the EGFR T790M mutation.

According to researchers, black and Hispanic patients are less likely to undergo guideline recommended PET/CT imaging at NSCLC diagnosis, which could partially explain differences in survival.

This study examined the association of disease progression and the deterioration of health-related quality of life for patients with metastatic breast, pancreatic, lung, and colorectal cancer.

Adults with advanced non-small cell lung cancer and impaired performance status experience significantly shorter survival after treatment with immune checkpoint inhibitors (ICIs) and receive ICIs more often than those with better performance status.

Although accumulating data continue to show immunotherapy as a major step forward in the treatment of patients with non–small cell lung cancer (NSCLC), questions regarding optimal sequencing and treatment duration still remain. At the 17th Annual Winter Lung Cancer Conference®, hosted by Physicians’ Education Resource®, LLC, multiple presentations looked for answers to address these issues.

This study found that carboplatin-pemetrexed treatment followed by pemetrexed maintenance was a valid option for first-line treatment of elderly patients with advanced nonsquamous non-small cell lung cancer.

Janssen Pharmaceutical Companies recently announced the FDA granted breakthrough therapy designation to JNJ-61186372, an EGFR-MET bispecific antibody, for the treatment of metastatic non-small cell lung cancer with EGFR exon 20 mutations.

The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.

A study, published in Nature Cancer, demonstrates the quick and evolving revolutions of resistance mechanisms in small cell lung cancer.

Researchers suggested that patients with non-small cell lung cancer (NSCLC) who have higher measures of tumor mutations that appear in a blood test generally have a better clinical response to PD-1-based immunotherapy than those with a lower measure of mutations.

The FDA Oncologic Drugs Advisory Committee voted 6 to 5 that ramucirumab plus erlotinib demonstrated a favorable benefit and risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer.